Tonix Pharmaceuticals Holding Corp. Quarterly report pursuant to Section 13 or 15(d)

STOCK BASED COMPENSATION (Tables)

9 Months Ended

Sep. 30, 2018

A summary of the stock option activity and related information for the Plans for the nine months ended September 30, 2018 is as follows:

	Shares		Weighted-Average Exercise Price		Weighted-Average Remaining Contractual Term		Aggregate Intrinsic Value
Outstanding at January 1, 2018		401,724	$	39.81		8.35	$	-
Grants		1,019,634	$	3.75			$	-
Exercised		-
Forfeitures or expirations		-		-
Outstanding at September 30, 2018		1,421,358	$	13.94		8.45	$	-
Vested and expected to vest at September 30, 2018		1,421,358	$	13.94		8.45	$	-
Exercisable at September 30, 2018		391,492	$	37.82		6.11	$	-

The assumptions used in the valuation of stock options granted during the nine months ended September 30, 2018 and 2017 were as follows:

	Nine Months Ended September 30, 2018		Nine Months Ended September 30, 2017
Risk-free interest rate		2.54% to 2.81%		1.75% to 2.29%
Expected term of option		4.50 to 7.00 years		5.00 to 7.91 years
Expected stock price volatility		99.65% to 109.22%		76.61% to 77.59%
Expected dividend yield		0.0%		0.0%